Clinical Trial Update: BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas [Phase 3]

View source ↗

Summary

Phase 3 trial updating the role of Brentuximab plus etoposide as first-line therapy for peripheral T-cell lymphoma; study is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Brentuximab vedotin (Adcetris) (brentuximab vedotin)
• Etoposide (Etoposide)

Snippet

Sponsor: N.N. Petrov National Medical Research Center of Oncology | Conditions: Peripheral T-cell Lymphoma | Phase 3 | Status: ENROLLING_BY_INVITATION